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culated. Per patient per month (PPPM) utilization rates were calculated based on
inpatient, outpatient and prescription data, and costs were estimated using Medi-
care reimbursement rates and Average Wholesale Price. RESULTS: A total of 5741
patientsmet the inclusion criteria. At least one HF re-hospitalizationwas observed
in 25% of patients, representing 85% of all-cause hospitalizations. Mean HF hos-
pital length of stay was 6.7 days at IH and 7.2 days at fourth HF re-hospitalization.
IH was most costly ($12,426) relative to the mean cost per subsequent HF re-hos-
pitalization ($9,832). HF re-hospitalization rates peaked at 0.062 PPPM 3-6 months
post IH. All-cause and HF-related outpatient visit rates peaked at 4.1 and 0.65 visits
PPPM, respectively, within threemonths after IH.Mean outpatient visit cost ranged
from$668 (0-3months) to $224 (18-24months post IH). Total pharmacy costs varied
from $593 PPPM (baseline period) to $848 PPPM (0-3 months post IH); of these,
cardiovascular drugs accounted for about one third ranging from $162 (baseline) to
$221 PPPM (0-3 months post IH). CONCLUSIONS: Treating elderly chronic HF pa-
tients is resource intensive and costly. Utilization and cost peak in the first three
months post IH. New interventions to improve health outcomes in the elderly HF
population hold the potential to decrease post IH resource utilization and save
costs.
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OBJECTIVES: Patients undergoing total knee or hip replacement are at high risk of
experiencing venous thromboembolism (VTE) - deep vein thrombosis (DVT) and
pulmonary embolism (PE), therefore, the aimof this studywas to estimate resource
utilization and associated costs of VTE following TKR under SUS perspective.
METHODS:Data analysis was conducted through a review of a government admin-
istrative claims database (DATASUS). A cohort of patients who underwent TKR
surgery in the public healthcare systemwas defined (1/2010 - 9/2010) and followed
for 6 months after surgery. Data regarding total hospitalization costs were com-
pared for patients who didn’t present complications with patients who presented
VTE events.RESULTS:A total of 4736 patientswere identified between January 2010
to September 2010 with average age of 65,6 years (SD 10,3), being 72.1% female.
Mean hospitalization costs per patientwere $BRL4,036 (SD 2,063) for the population
analyzed. VTE episodes were experienced by 42 patients (0,89%, 32 cases of DVT
and 10 of PE) and were associated with higher hospitalizations costs than patients
without any complication: $BRL3,919 (SD 1,811), $BRL4,581 (SD 2,362) and
$BRL7,715 (SD 6,777) for patients without complication, DVT and PE respectively.
CONCLUSIONS: Patients experiencing VTE following TKR surgery represents a sig-
nificant economic burden for the Brazilian public health care system. Our study
suggests that a patient who presents PE following TKR surgery can cost twicemore
than a patient without complications.
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OBJECTIVES: Hypertension is the most important risk factor in the preventable
cardiovascular risks. In the study, consumption analysis of the products contains
ARB and ACEI was performed and factors effecting the budget chance was calcu-
lated with a regression analysis for assessment the current situation.METHODS:A
computer base analysis was conducted depending on consumption data of ARB
and ACEI which were taken from Information Medical Statisticis – Health (IMS) in
2005-2010 years by using Windows Office Excel 2007. Regression analysis was per-
formed with the results of conducted analysis by using SPSS 15.00 for Windows.
RESULTS: Losartan consumption in unit, however, was rised 40%, consumption in
TL was decreased 47% in years. Consumption of Ramipril molecule in unit rised
71,2% and TL consumption decreased 31,7% from year 2005 to 2010, even the pos-
itive marketing effects of new generic molecules were launched. It was shown in
the regression analysis that new launched generics had a negative effect to budget
of ARB and ACEI. The formula of percentage chance of the budget of ARB and ACEI
market was calculated as PCB  NPLY*(-0,07)  PCY*(1,248)  CC*(0,936). BC: Per-
centage Chance of Budget, NPLY: New Product Number Launched in Years, PCY 
Percentage Chance of Price in Years, CC  Percentage Chance of Consumption in
Years. CONCLUSIONS: Effect of hypertension to Turkey‘s health budget is rising
day by day due both rising diagnosis and comorbidites. On the other hand, it was
shown that launching new generics has an important impact on controlling health
budget.
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OBJECTIVES: Aim of this study was to evaluate the average annual direct costs of
treating patients with a recent admission for acute coronary syndrome (ACS).
METHODS: Direct medical costs of patients with ACS (index event) in the period
January 1, 2008 to December 31, 2008 and treated with dual antiplatelet therapy
(clopidogrelaspirin)were estimated in a one-year follow-upperiod. Resource con-
sumption measured were: reimbursed drugs, diagnostic procedures, hospitaliza-
tions. The analysis was performed from the Italian National Health Service (INHS)
perspective. RESULTS: A total of 2,758,872 subjects were observed; 7,082 (35.8%
females) of thesewere hospitalized for ACSduring the 1-year accrual period (2.6‰).
Among patients with ACS, 60% were medically treated, 33.1% were treated with
percutaneous coronary intervention (PCI) and 6.9% died during the first hospital-
ization. Dual antiplatelet treatment was prescribed in 25.9% of patients with ACS
medically treated and in 70.1% of patients with ACS treated with PCI. During fol-
low-up, all-cause mortality rate was 5.7% [33% for cardiovascular (CV) causes];
among the 58.6% of patients with at least one re-hospitalization, 18.4% had a re-
current episode of ACS, 24.8% had other CV episodes and 15.4% were hospitalized
for non-CV reasons. Average yearly cost/patient for total ACS population was
12,673€/year (drugs: 1,896€, hospitalizations: 10,315€, diagnostic: 462€). For patients
with an index event of ACS medically treated, average annual cost was 11,043€/
year (drugs: 1,968€, hospitalizations: 8,558€, diagnostic: 517€) and for patients with
ACS treated with PCI, average annual cost per patient was 13,776€/year (drugs:
1,848€, hospitalizations: 11,492€, diagnostic: 436€). Hospitalization costs of patients
with a relapse were at least 49% higher than for patients without events. Patients
died for a CV event during follow-up had an average cost of 19,198€/patient.
CONCLUSIONS: Patients with ACS had relevant costs of management being the
need for a new hospitalization the major cost driver.
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OBJECTIVES: Traditionally, newly referred naïve anticoagulation patients (warfa-
rin use for2 months) received anticoagulation education via 30-min face-to-face
pharmacist counseling (Method I).We hypothesized that a new education program
with 15-min video education plus 15-min face-to-face pharmacist counseling
(Method II) would maximize operational revenues via increased scheduling capac-
ity leading to increased clinic visits while maintaining clinic efficiency and quality
education. This study aimed to compare operational revenues, clinical outcomes
and anticoagulation knowledge levels in patients receiving two anticoagulation
education methods. METHODS: This IRB-approved study employed a parallel-
group, pre-post design. Knowledge levels were evaluated using the previously val-
idated Short-form Oral Anticoagulation Knowledge Test (SOAK) before and after
education. Revenues and clinical outcomes were measured during the implemen-
tation of Method I or II. A sample size of 106 patients was required to detect a 15%
change in knowledge with 80% power and alpha of 0.05. RESULTS: There were 108
patients (Method I:II54:54) with similar baseline demotaphics: female (52.3%),
65 years-old (52.8%) and high school education (67.9%). Clinical measures re-
main stable between twoMETHODS:major bleeding rate (0.3%), thromboembolism
rate (0.4%) and patients within target INR (63%). A 3.39% increased monthly rev-
enues was observed in Method II compared to Method I, due to increased clinic
visits (12.97%) among newly referred naïve patients, yet total patient volume of
other types decreased (-2.95%). The pre-visit SOAK scores were similar between
Methods (p0.383). Both Methods significantly improved SOAK scores (Method I:
pre 55.9%26%/post 75.8%21%, p0.001; Method II pre 60.4%26%/post
70.7%22%, p0.030). Mean changes in pre-post SOAK scores were significantly
higher in Method I (21%23%) than in Method II (10%23%, p0.011).
CONCLUSIONS: The new education program (Method ii) resulted in increased rev-
enues via increased clinic visits among newly referred patients. Improved antico-
agulation knowledge levels using Method II were acceptable without adverse im-
pacting on safety and clinical outcomes.
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OBJECTIVES: Pharmacists play an integral role in quality improvement programs
through medication therapy management services (MTM). This study estimates
the effect of a pharmacist-led and delivered MTM program on achieving Optimal
Diabetes Care (ODC). METHODS: The study included patients with diabetes who
receivedMTM services at Fairview Clinics during a 2007 demonstration project (n
121) and those invited to receive MTM services but opted out (n 103). Baseline
characteristicswere compared between the two groups. Rates of ODC for 2006, 2007
and 2008 were compared using McNemar’s test based on Minnesota Community
Measurement all-or-none 5-component (D5) ODC measure (HbA1c 7%;
LDL100mg/dl; blood pressure140/90mmHg; tobacco free; and daily aspirin use).
Linear and Nonlinear multivariate difference-in-differences (DID) estimation were
used to evaluate the impact of one-year exposure toMTMon each component of D5
ODCmeasure. RESULTS: The MTM group had more co-morbidities, more complex
medication regimens and a higher percentage of diabetes with complications
(p0.05). There was significant improvement in ODC rates for the MTM group in
2007 compared to 2006 (45.45%vs.21.49%, p0.001) and a significant decline in 2008
(45.45% vs. 25.62%, p0.0002). The control group showed a significant improve-
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ment in 2007 compared to 2006 (39.81% vs.24.27%, p0.0002) and a non-significant
decline in 2008 (39.81% vs. 30.10%, p0.077). Non-Linear DID models showed that
MTM patients were more likely to meet the HbA1c criterion in 2007 (OR: 2.48, 95%
CI: 1.04-5.85, p0.038). Linear DID models for HbA1c showed a mean reduction of
0.54% (95% CI: 0.091%-0.98%, p0.018) for MTM patients. Among MTM patients,
rates of meeting HbA1c criterion in 2008 declined to baseline values.
CONCLUSIONS: Despite their greater complexity, optimal diabetes care signifi-
cantly improved among patients who were exposed to MTM. Drop in optimal
HbA1c control after discontinuation ofMTM exposure highlights the importance of
regular access to MTM services.
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OBJECTIVES:Tobacco control policies have focused on a combination of a variety of
initiatives such as monitoring, smoke-free public sites, cessation programmes,
health warnings, advertising bans and taxation. Smoking cessation treatments are
also recommended, as smokers who try to quit without help often fail in their
attempt.METHODS: TOSCA has been developed as an open or closed cohort semi-
Markov model, where current and former smokers may quit or relapse in their
smoking status over time. The impact of a tobacco policy on the quit rate is mod-
elled using the tobacco control scale (TCS) which has been shown to correlate with
quit ratios. Smoking prevalence, demographic inputs and mortality rates are de-
rived from published literature. The model predicts smoking prevalence, cumula-
tive smoking attributable deaths and morbidities over time (lung cancer, stroke,
coronary heart disease and chronic obstructive pulmonary disease). The impact of
tobacco control policies can be assessed over a 60 year horizon. RESULTS: Each one
point increase in TCS reduces smoking prevalence in both the open and closed
cohort model by 0.05% in absolute terms. This reduces cumulative smoking attrib-
utable mortality by 0.08% at 20 years and 0.13% at 60 years for lung cancer. Similar
results were obtained for stroke, COPD and CHD. For the UK this results in 10,069
and 8,908 fewer deaths in the open and closed cohort models respectively. Reduc-
tion in morbidities was slightly higher particularly for stroke where there was a
1.4% and 2.0% reduction in events at 20 and 60 years respectively. CONCLUSIONS:
Comprehensive smoking cessation policy is instrumental in reducing smoking
prevalence, mortality and morbidity. The TOSCAmodel can demonstrates the im-
pact of tobacco policy on smoking prevalence, mortality and morbidity for several
European countries.
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OBJECTIVES: The objective of this research was to examine differences in patterns
of statin prescribingbetween Northern Ireland and England both before and after
the introduction of the Quality and Outcomes Framework (QOF)METHODS:North-
ern Ireland practices were matched with practices in England, statin prescribing
data and QOF achievement scores (for the first year post-QOF) were obtained.
Crude prescribing data frommatched practicesweremanipulated to provide a data
set of Defined Daily Doses (DDDs)/1000 patients and cost/DDD/1000 patients for
each statin drug entity covering 1 year before and after the introduction of QOF.
QOF achievements were converted into percentage scores for matched practices.
Main outcome measure: Cost per defined daily dose (DDD) per 1,000 patients
RESULTS: Significantly less statins (DDD/1,000 patients) were dispensed in North-
ern Ireland comparedwith thematched region in England both before and after the
introduction of QOF (P 0.001). Significantly more statins, however, were dis-
pensed in both regions after the introduction of QOF. As a result of the introduction
of QOF, the cost/DDD/1000 patients rose by £13.17 in NI, but fell by £3.76 in the
matched region in England. CONCLUSIONS: Strategies should be considered to
educate prescribers on cost-effectiveness by increasing their awareness of the neg-
ative budgetary impact resulting from early adoption of new and expensive statins
and by encouraging generic prescribing.
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OBJECTIVES: In Ukraine cardiovascular diseases occupy a leading place in the
structure of death rate (25,9 %) and are one of most reasons of country depopula-
tion. From data of evidence-basedmedicine application of hypolipidemic prepara-
tions of statins in complex therapy of cardiovascular diseases and for the prophy-
laxis of their complications assists the decline of both common and cardiovascular
death rate. The aim of this research is a choice the optimal preparations from the
statins for the secondary prophylaxis of acute coronary syndrome on the basis of
cost-minimization analysis results in Ukraine. METHODS: Cost-minimization
analysis of hypolipidemic therapy with statins for the secondary prophylaxis of
acute coronary syndrome. The objects are results of a fewmeta-analyses andmul-
ticentral clinical trials: STELLAR, MERCURY, GREACE, 4S (Scandinavian Simvasta-
tin Survival Study); preparations of statins presented at the pharmaceuticalmarket
of Ukraine. The prices on preparations were taken from the price-lists (October,
2010). RESULTS: The analysis of meta-analyses and multicentral clinical trials re-
sults of atorvastatin, simvastatin and rosuvastatin preparations showed that these
preparations have practically equal clinical effectiveness for the secondary pro-
phylaxis of acute coronary syndrome. The results of cost-minimization analysis
showed that the costs for preparations of atorvastatin were less than the costs for
preparations of simvastatin and rosuvastatin. The hypolipidemic therapy with
rosuvastatin are the most expensive. The costs for the course of prophylaxis by
preparations of simvastatin are less, than the costs for the course of prophylaxis by
rosuvastatin and more, than the costs for prophylaxis by atorvastatin.
CONCLUSIONS: Generic preparations of atorvastatin are the least expense among
others statins presented at the pharmaceutical market of Ukraine, and remain
preparations of choice for the prophylaxis of acute coronary syndrome.
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OBJECTIVES: To assess the impact of receiving emotional support on self-per-
ceived current health status and physical and mental health wellness among
adults with cardiovascular disorders (CVD) in the United States. METHODS: We
identified adults aged 40 years with CVD (i.e., self-reported stroke, congestive
heart failure, coronary heart disease or heart attack) in the 2007-2008 National
Health and Nutrition Examination Survey (NHANES), a nationally representative
survey of the non-institutionalized US population. Outcome measures including
self-reported current health status (poor [fair/poor] vs. good [good/very good/ex-
cellent]), days with poor physical health, days with poor mental health, and inac-
tive days due to poor physical/mental health, were compared between CVD pa-
tients receiving and not receiving emotional support using appropriate univariate
tests. All analyses were stratified by patient demographics, including gender and
race. National estimates were obtained using sample weights. RESULTS: In 2007-
2008, 12.4% (Population Estimate16.6 million; 95% CI: 14.2-19.0 million) of the US
population40 years of age had self-reported CVD, of which92% denoted having
someone (e.g., spouse, neighbor) provide emotional support, with the proportion
greater among females thanmales (93.7% vs. 89.8%; P0.188). Among CVD patients
not receiving emotional support, a greater proportion reported current health sta-
tus as ‘poor’ compared with patients receiving emotional support (51.2% vs. 34.6%;
P0.091). Similarly, compared with CVD patients receiving emotional support, the
number of dayswith poor physical health (6.9 vs. 12.3 days; P0.014),mental health
(4.4 vs. 7.8 days; P0.137), and inactive days (4.4 vs. 9.5 days; P0.101) were each2
times greater among patients not receiving emotional support. CONCLUSIONS: A
majority patients with CVD diagnosis reported receiving some emotional support,
with receipt of emotional support being associated with improved health status.
Health care providers (e.g., physicians, pharmacists) should emphasize the value of
emotional support to patientswith CVD,whichmay help in improving the physical
and mental well-being of these patients.
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OBJECTIVES: The objective of this study is to assess scope and role of drug thera-
pies in cardiology/vascular diseases in AOTM works. AOTM is one of a light touch
HTA Agencies around the world with respect to drugs evaluation before desion-
taking on reimbursement and pricing. AOTM stands for quality assurance of HTA
reports developed by industry applying for inclusion of drugs to BBP (basic benefit
package). It deals also with appraisal of submitted evidence. AOTM does not de-
velop HTA reports from the scratch with respect to drugs. Therefore no priority
setting process is needed and no bias in selection of topics for assessment should
be in place.METHODS:Among recommendations of AOTMpublished until the end
of 2011 we analyzed all related to cardiovascular drugs. RESULTS: Among 400
AOTM decisions verified only 31 (8%) were related to cardiovascular drugs. Recom-
mendation regarding non–drug technologies were issued to 47 (12%) of 400 tech-
nologies. 58 (15%) applied to drugs used in the treatment of nervous disorders, 34
(9%) metabolic disorders, 21 (5%) genito-urinary system. The largest number (142/
36% of 400) of analyzed submission was connected with antineoplastic and immu-
nomodulating agents; 105 (74%) of them regarding oncology treatment. Fifteen
percent of verified docummentations applied to other, single indications.
CONCLUSIONS: The influence of cardiovascular drugs for AOTM recommendations
were not significant and no bias with respect to special focus on cardiovascular drugs
has been observed in comparision to focus on other medicines. Most of commissions
prepared by AOTM were related to antineoplastic (cancer chemotherapy) treatment
representing normal trends in research and development in medicine.
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